​

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRTX Stock Forecast

Vertex Pharmaceuticals (VRTX) stock forecast, based on 56 Wall Street analysts, predicts a 12-month average price target of $580.20, with a high of $665.00 and a low of $350.00. This represents a 5.32% increase from the last price of $550.87.

$350 $420 $490 $560 $630 $700 High: $665 Avg: $580.2 Low: $350 Last Closed Price: $550.87

VRTX Stock Rating

Vertex Pharmaceuticals stock's rating consensus is Buy, based on 56 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 48 Buy (85.71%), 7 Hold (12.50%), 1 Sell (1.79%), and 0 Strong Sell (0.00%).

Buy
Total 56 1 7 48 Strong Sell Sell Hold Buy Strong Buy

VRTX Price Target Upside V Benchmarks

TypeNameUpside
StockVertex Pharmaceuticals5.32%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts21048
Avg Price Target$634.50$622.90$560.77
Last Closing Price$550.87$550.87$550.87
Upside/Downside15.18%13.08%1.80%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2662041132
Oct, 2662041132
Sep, 2641941129
Aug, 2641941129
Jul, 2662141133
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 03, 2026Carter GouldCantor Fitzgerald$619.00$535.4215.61%12.37%
Nov 03, 2026Mohit BansalWells Fargo$650.00$553.1517.51%18.00%
Oct 08, 2026RBC Capital$576.00$502.6214.60%4.56%
Sep 28, 2026UBS$615.00$528.0416.47%11.64%
Sep 23, 2026Akash TewariJefferies$640.00$514.9924.27%16.18%
Sep 22, 2026Andrew FeinH.C. Wainwright$641.00$519.6723.35%16.36%
Sep 01, 2026Terence FlynnMorgan Stanley$665.00$547.6521.43%20.72%
Sep 01, 2026Goldman Sachs$653.00$544.5219.92%18.54%
Aug 11, 2026Jeffrey WalchBernstein$608.00$530.2914.65%10.37%
Aug 10, 2026Andy ChenWolfe Research$562.00$522.787.50%2.02%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 03, 2026Cantor FitzgeraldOverweightOverweighthold
Nov 03, 2026Wells FargoOverweightOverweighthold
Nov 03, 2026Cowen & Co.BuyBuyhold
Oct 12, 2026Bank of America SecuritiesBuyBuyhold
Oct 08, 2026RBC CapitalOutperformOutperformhold
Sep 28, 2026UBSBuyBuyhold
Sep 23, 2026JefferiesBuyBuyhold
Sep 22, 2026BMO CapitalOutperformOutperformhold
Sep 01, 2026Goldman SachsBuyBuyinitialise
Aug 12, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $2 $9 $16 $23 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.09$12.97$14.05$-2.08$15.46---
Avg Forecast$12.96$14.60$15.03$0.48$18.47$20.49$22.97$25.82
High Forecast$14.54$16.11$15.40$1.12$19.96$25.45$28.82$29.56
Low Forecast$12.26$13.86$14.65$0.06$16.67$17.06$19.12$24.25
Surprise %-29.86%-11.16%-6.52%-533.33%-16.30%---

Revenue Forecast

$7B $9B $11B $13B $15B $17B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.57B$8.93B$9.87B$11.02B$12.00B---
Avg Forecast$7.50B$8.93B$9.86B$10.89B$11.77B$12.86B$13.94B$15.25B
High Forecast$8.21B$9.64B$9.91B$10.97B$13.68B$12.87B$14.04B$16.94B
Low Forecast$7.19B$8.58B$9.79B$10.85B$11.22B$12.85B$13.85B$14.53B
Surprise %0.97%-0.03%0.06%1.17%1.97%---

Net Income Forecast

$-1B $800M $3B $4B $6B $8B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.34B$3.32B$3.62B$-535.60M$3.95B---
Avg Forecast$2.08B$2.40B$3.62B$153.32M$4.77B$4.87B$5.30B$6.73B
High Forecast$2.50B$2.88B$4.34B$291.61M$5.20B$6.63B$7.51B$7.70B
Low Forecast$1.66B$1.92B$2.90B$15.03M$4.34B$4.44B$4.98B$6.32B
Surprise %12.58%38.24%--449.33%-17.14%---

VRTX Forecast FAQ

Is Vertex Pharmaceuticals stock a buy?

Vertex Pharmaceuticals stock has a consensus rating of Buy, based on 56 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 48 Buy, 7 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Vertex Pharmaceuticals is a favorable investment for most analysts.

What is Vertex Pharmaceuticals's price target?

Vertex Pharmaceuticals's price target, set by 56 Wall Street analysts, averages $580.2 over the next 12 months. The price target range spans from $350 at the low end to $665 at the high end, suggesting a potential 5.32% change from the previous closing price of $550.87.

How does Vertex Pharmaceuticals stock forecast compare to its benchmarks?

Vertex Pharmaceuticals's stock forecast shows a 5.32% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vertex Pharmaceuticals over the past three months?

  • November 2026: 18.75% Strong Buy, 62.50% Buy, 12.50% Hold, 3.12% Sell, 3.12% Strong Sell.
  • October 2026: 18.75% Strong Buy, 62.50% Buy, 12.50% Hold, 3.12% Sell, 3.12% Strong Sell.
  • September 2026: 13.79% Strong Buy, 65.52% Buy, 13.79% Hold, 3.45% Sell, 3.45% Strong Sell.

What is Vertex Pharmaceuticals’s EPS forecast?

Vertex Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $20.49, marking a 32.54% increase from the reported $15.46 in 2025. Estimates for the following years are $22.97 in 2027, and $25.82 in 2028.

What is Vertex Pharmaceuticals’s revenue forecast?

Vertex Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $12.86B, reflecting a 7.17% increase from the reported $12B in 2025. The forecast for 2027 is $13.94B, and $15.25B for 2028.

What is Vertex Pharmaceuticals’s net income forecast?

Vertex Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $4.87B, representing an 23.31% increase from the reported $3.95B in 2025. Projections indicate $5.3B in 2027, and $6.73B in 2028.